医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FRAMINGHAM, Mass.

Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will be making presentations at several healthcare and scientific conferences in Asia during October, highlighting biotechnology innovation and drug development for Alzheimer’s disease.

Event:
BioCentury China Healthcare Summit

• Title: Panel: International Perspective: Voices from Abroad
• Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
• Date: Tuesday, October 18, at 5:05 p.m., local time
• Location: Grand Hyatt Shanghai, Shanghai, China

Event:
10^th International Congress of The Asian Society Against Dementia

• Title: Symposium: Phase 3 Development of ALZ-801: Targeting Amyloid Pathology of Alzheimer’s Disease with an Oral Anti-Aggregation Agent
• Presenters:
  Serge Gauthier, MD, FRCPC, Director of the Alzheimer’s Disease Research Unit at McGill University in Montreal, Canada, and member of Alzheon’s Scientific Advisory Board;
  Susan Abushakra, MD, Chief Medical Officer of Alzheon;
  Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
• Date: Saturday, October 22, at 12:00 noon, local time
• Location: Hangzhou Haiwaihai Crown Hotel, Hangzhou, China

Event:
China Renaissance Healthcare and Life Sciences Leadership Summit

• Title: Panel: Overseas Biotechnology Sector
• Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
• Date: Thursday, October 27, 2016 at 3:15 p.m.– 4:30 p.m., local time
• Location: Dongjiao State Guest Hotel, Shanghai, China

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005167/en/